Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus BCG versus BCG alone in persistent or recurrent high-risk non-muscle-invasive bladder cancer
CTR20212253Phase 3Suspended
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab, bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), transitional cell carcinoma (TCC), sponsored by Bristol Myers Squibb. Started Sep 2021; status: suspended.
02
Drugs
nivolumabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20212253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212253.